Pharmaceuticals Global On demand · 24-48h

Global D(-) Alpha Parahydroxy Phenylglycine Market Strategic Research Report

Global D(-) Alpha Parahydroxy Phenylglycine Market Strategic…
$3,500 USD
Market Research Reports
Strategic Research Report
Global D(-) Alpha Parahydroxy Phenylglycine Market
$2682025
5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Content 98.5%, Content 99%

By Application: Amoxicillin, Cephalosporins

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Apeloa Pharmaceutical, Henan Newland Pharmaceutical, Shanxi Xinbaoyuan Pharmaceutical, Zhejiang Yuntao Biotechnology, Deretil, Daurala Organics, Anhui Jingke Biotechnology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 93 pages
Market size 2025
$268
Million USD
Forecast CAGR
5%
2025-2032
Forecast 2032
$377.1
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global D(-) Alpha Parahydroxy Phenylglycine market size is predicted to grow from US$ 268 million in 2025 to US$ 374 million in 2032; it is expected to grow at a CAGR of 5.0% from 2026 to 2032.

D(-) Alpha Parahydroxy Phenylglycine is the D-enantiomer of 4-hydroxyphenylglycine. It is a non-proteinogenic amino acid found in Herpetosiphon aurantiacus.

Main Manufacturers:

The global D(-) Alpha Parahydroxy Phenylglycine market presents an oligopolistic situation. At present, the global key players are mainly distributed in China, among which Apeloa Pharmaceutical is the largest manufacturer of this product, accounting for about 40% of the global market share in 2024.

Market Trend and Drivers:

1. Growing Demand: The demand for D(-) Alpha Parahydroxy Phenylglycine is steadily increasing due to the expanding global antibiotic market, especially the wide usage of semi-synthetic β-lactam antibiotics like amoxicillin.

2. Preference for Green Production: The biosynthesis method of amoxicillin API is gradually becoming the mainstream due to its environmental advantages, which is expected to further boost the demand for D(-) Alpha Parahydroxy Phenylglycine methyl ester used in this process.

3. Increasing Market Concentration: Chinese manufacturers play a significant role in the global market. Leading enterprises in the industry are continuously expanding their scale and improving technology, leading to a gradual increase in market concentration, and the market share of top companies is likely to further expand.

Main Applications:

Amoxicillin production: It is the main application area of ​​​​L-para-hydroxyphenylglycine, which is used to synthesize amoxicillin raw materials and then produce various amoxicillin preparations.

Cephalosporin antibiotic production: It is also important in the synthesis of cephalosporin antibiotics such as cefoperazone, cefoperazone, and cefprozil. With the growth of market demand for these cephalosporin antibiotics, the demand for L-para-hydroxyphenylglycine has also increased accordingly.

This report presents a comprehensive overview of the global D(-) Alpha Parahydroxy Phenylglycine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Content 98.5%
  • Content 99%

Segment by Application

  • Amoxicillin
  • Cephalosporins

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global D(-) Alpha Parahydroxy Phenylglycine market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Amoxicillin, Cephalosporins evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global D(-) Alpha Parahydroxy Phenylglycine Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$268
2025
Forecast
$377.1
2032
CAGR
5%
2025–2032
Regions
5
global
Key companies
Apeloa PharmaceuticalHenan Newland PharmaceuticalShanxi Xinbaoyuan PharmaceuticalZhejiang Yuntao BiotechnologyDeretilDaurala OrganicsAnhui Jingke Biotechnology
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Content 98.5%Content 99%
By Application
AmoxicillinCephalosporins

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Content 98.5%
  • 3.1.3 Content 99%
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Amoxicillin
  • 4.1.3 Cephalosporins
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Apeloa Pharmaceutical
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Henan Newland Pharmaceutical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Shanxi Xinbaoyuan Pharmaceutical
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Zhejiang Yuntao Biotechnology
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Deretil
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Daurala Organics
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Anhui Jingke Biotechnology
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global D(-) Alpha Parahydroxy Phenylglycine market?
The global D(-) Alpha Parahydroxy Phenylglycine market is estimated at US$ 268 million in 2025 (base year) and is projected to reach US$ 374 million by 2032.
What is the forecast CAGR for the D(-) Alpha Parahydroxy Phenylglycine market?
The market is expected to grow at a CAGR of 5.0% from 2026 to 2032, expanding from US$ 268 million in 2025 to US$ 374 million in 2032, roughly 1.4 times its base-year value.
What is D(-) Alpha Parahydroxy Phenylglycine?
D(-) Alpha Parahydroxy Phenylglycine is the D-enantiomer of 4-hydroxyphenylglycine. It is a non-proteinogenic amino acid found in Herpetosiphon aurantiacus.
How is the D(-) Alpha Parahydroxy Phenylglycine market segmented by type?
By type, the market is segmented into Content 98.5% and Content 99%.
What are the key applications of D(-) Alpha Parahydroxy Phenylglycine?
Key applications covered include Amoxicillin and Cephalosporins.
Which companies are profiled in the D(-) Alpha Parahydroxy Phenylglycine market report?
Key players profiled include Apeloa Pharmaceutical, Henan Newland Pharmaceutical, Shanxi Xinbaoyuan Pharmaceutical, Zhejiang Yuntao Biotechnology, Deretil, Daurala Organics and Anhui Jingke Biotechnology.
What geographies does the D(-) Alpha Parahydroxy Phenylglycine market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the D(-) Alpha Parahydroxy Phenylglycine market report?
The report is intended for manufacturers and solution providers, distributors and end users in Amoxicillin and Cephalosporins, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the D(-) Alpha Parahydroxy Phenylglycine market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.